Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions | MicrobiomeTrials← Back to trialsNCT07888335
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-12-10Est. Completion: 2028-06-30
Enrollment target: 20 participants Locations- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Other microbiome trials you might be interested in
Kidney Disease
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of pr…
Birmingham, United StatesEst. completion Sep 7, 2028
Immunoglobulin A Nephropathy
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropath…
Multiple LocationsEst. completion Aug 13, 2028